517 related articles for article (PubMed ID: 10811379)
21. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study.
Garcia-Borreguero D; Larrosa O; Williams AM; Albares J; Pascual M; Palacios JC; Fernandez C
Neurology; 2010 Jun; 74(23):1897-904. PubMed ID: 20427750
[TBL] [Abstract][Full Text] [Related]
22. Excessive Daytime sleepiness in idiopathic restless legs syndrome: characteristics and evolution under dopaminergic treatment.
Kallweit U; Siccoli MM; Poryazova R; Werth E; Bassetti CL
Eur Neurol; 2009; 62(3):176-9. PubMed ID: 19602890
[TBL] [Abstract][Full Text] [Related]
23. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Japanese restless legs syndrome patients with cabergoline: an open clinical preliminary trial.
Aizawa H; Aburakawa Y; Suzuki Y; Enomoto H; Makita Y; Kikuchi K; Kimura T; Yahara O
Intern Med; 2006; 45(7):453-5. PubMed ID: 16679700
[TBL] [Abstract][Full Text] [Related]
25. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.
Polo O; Ylä-Sahra R; Hirvonen K; Karvinen J; Vahteristo M; Ellmén J
Clin Neuropharmacol; 2007; 30(6):335-44. PubMed ID: 18090458
[TBL] [Abstract][Full Text] [Related]
26. Night-to-night variability in periodic leg movements in patients with restless legs syndrome.
Sforza E; Haba-Rubio J
Sleep Med; 2005 May; 6(3):259-67. PubMed ID: 15854857
[TBL] [Abstract][Full Text] [Related]
27. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
28. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.
Benes H
Sleep Med; 2006 Jan; 7(1):31-5. PubMed ID: 16194624
[TBL] [Abstract][Full Text] [Related]
29. Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.
Manconi M; Ferri R; Zucconi M; Clemens S; Giarolli L; Bottasini V; Ferini-Strambi L
Neurology; 2011 Jul; 77(2):110-7. PubMed ID: 21715702
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of idiopathic and uremic restless legs syndrome with L-dopa--a double-blind cross-over study].
Wetter TC; Trenkwalder C; Stiasny K; Pollmächer T; Kazenwadel J; Kohnen R; Künzel M; Oertel WH
Wien Med Wochenschr; 1995; 145(17-18):525-7. PubMed ID: 8588396
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome.
García-Borreguero D; Kohnen R; Högl B; Ferini-Strambi L; Hadjigeorgiou GM; Hornyak M; de Weerd AW; Happe S; Stiasny-Kolster K; Gschliesser V; Egatz R; Cabrero B; Frauscher B; Trenkwalder C; Hening WA; Allen RP
Sleep Med; 2007 Aug; 8(5):455-63. PubMed ID: 17543579
[TBL] [Abstract][Full Text] [Related]
32. Leg movements during wakefulness in restless legs syndrome: time structure and relationships with periodic leg movements during sleep.
Ferri R; Manconi M; Plazzi G; Bruni O; Cosentino FI; Ferini-Strambi L; Zucconi M
Sleep Med; 2012 May; 13(5):529-35. PubMed ID: 22341907
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study.
Trenkwalder C; Hundemer HP; Lledo A; Swieca J; Polo O; Wetter TC; Ferini-Strambi L; de Groen H; Quail D; Brandenburg U;
Neurology; 2004 Apr; 62(8):1391-7. PubMed ID: 15111679
[TBL] [Abstract][Full Text] [Related]
35. Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients.
Hornyak M; Hundemer HP; Quail D; Riemann D; Voderholzer U; Trenkwalder C
Clin Neurophysiol; 2007 Jul; 118(7):1532-7. PubMed ID: 17531532
[TBL] [Abstract][Full Text] [Related]
36. Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome.
Nardone R; Ausserer H; Bratti A; Covi M; Lochner P; Marth R; Tezzon F
Acta Neurol Scand; 2006 Oct; 114(4):244-9. PubMed ID: 16942543
[TBL] [Abstract][Full Text] [Related]
37. [Effect of high dose pergolide mesilate on restless legs syndrome associated with Parkinson disease].
Imamura A; Tsuboi Y; Tanaka M; Obata T; Yamada T
Rinsho Shinkeigaku; 2007 Apr; 47(4):156-9. PubMed ID: 17511286
[TBL] [Abstract][Full Text] [Related]
38. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
[TBL] [Abstract][Full Text] [Related]
39. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial.
Merlino G; Dolso P; Canesin R; Cancelli I; Valente M; Gigli GL
Neuropsychobiology; 2006; 54(3):195-200. PubMed ID: 17314491
[TBL] [Abstract][Full Text] [Related]
40. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
